nach oben

Erschienen in:

01.10.2011 | Topic Paper

Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU)

verfasst von: Pasquale Martino, Vincenzo Scattoni, Andrea B. Galosi, Paolo Consonni, Carlo Trombetta, Silvano Palazzo, Carmen Maccagnano, Giovanni Liguori, Massimo Valentino, Michele Battaglia, Libero Barozzi

Erschienen in: World Journal of Urology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Defining the site of recurrent disease early after definitive treatment for a localized prostate cancer is a critical issue as it may greatly influence the subsequent therapeutic strategy or patient management.

Methods

A systematic review of the literature was performed by searching Medline from January 1995 up to January 2011. Electronic searches were limited to the English language, and the keywords prostate cancer, radiotherapy [RT], high intensity focused ultrasound [HIFU], cryotherapy [CRIO], transrectal ultrasound [TRUS], magnetic resonance [MRI], PET/TC, and prostate biopsy were used.

Results

Despite the fact that diagnosis of a local recurrence is based on PSA values and kinetics, imaging by means of different techniques may be a prerequisite for effective disease management. Unfortunately, prostate cancer local recurrences are very difficult to detect by TRUS and conventional imaging that have shown limited accuracy at least at early stages. On the contrary, functional and molecular imaging such as dynamic contrast-enhanced MRI (DCE–MRI), and diffusion-weighted imaging (DWI), offers the possibility of imaging molecular or cellular processes of individual tumors.

Recently, PET/CT, using 11C-choline, 18F-fluorocholine or 11C-acetate has been successfully proposed in detecting local recurrences as well as distant metastases. Nevertheless, in controversial cases, it is necessary to perform a biopsy of the prostatic fossa or a biopsy of the prostate to assess the presence of a local recurrence under guidance of MRI or TRUS findings.

Conclusion

It is likely that imaging will be extensively used in the future to detect and localize prostate cancer local recurrences before salvage treatment.

Lightner DJ, Lange PH, Reddy PK, Moore L (1990) Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 144(4):921–926PubMed

Abi-Aad AS, Macfarlane MT, Stein A, de Kernion JB (1992) Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 147(3 Pt 2):952–955PubMed

Wasserman NF, Kapoor DA, Hildebrandt WC, Zhang G, Born KM, Eppel SM, Reddy PK (1992) Transrectal US in evaluation of patients after radical prostatectomy. Part II. Transrectal US and biopsy findings in the presence of residual and early recurrent prostatic cancer. Radiology 185(2):367–372

Wasserman NF, Kapoor DA, Hildebrandt WC, Zhang G, Born KM, Eppel SM, Reddy PK (1992) Transrectal US in evaluation of patients after radical prostatectomy. Part I. Normal postoperative anatomy. Radiology 185(2):361–366PubMed

Salomon CG, Flisak ME, Olson MC, Dudiak CM, Flanigan RC, Waters WB (1993) Radical prostatectomy: transrectal sonographic evaluation to assess for local recurrence. Radiology 189(3):713–719PubMed

Foster LS, Jajodia P, Fournier G Jr, Shinohara K, Carroll P, Narayan P (1993) The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 149(5):1024–1028PubMed

Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR (2001) Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol 166(1):111–115PubMedCrossRef

Fowler JE Jr, Brooks J, Pandey P, Seaver LE (1995) Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 153(3 Pt 2):1011–1014PubMedCrossRef

Wood DP Jr, Peretsman SJ, Seay TM (1995) Incidence of benign and malignant prostate tissue in biopsies of the bladder neck after a radical prostatectomy. J Urol 154(4):1443–1446PubMedCrossRef

10.

Lepor H, Chan S, Melamed J (1998) The role of bladder neck biopsy in men undergoing radical retropubic prostatectomy with preservation of the bladder neck. J Urol 160(6 Pt 2):2435–2439PubMed

11.

Laufer M, Pound CR, Carducci MA, Eisenberger MA (2000) Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 55(3):309–315PubMedCrossRef

12.

Pound CR, Christens-Barry OW, Gurganus RT, Partin AW, Walsh PC (1999) Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol 162(4):1337–1340

13.

Ferguson JK, Oesterling JE (1994) Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. Urol Clin North Am 21(4):677–685PubMed

14.

Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R (1989) The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141(4):873–879PubMed

15.

Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43(5):649–659PubMedCrossRef

16.

Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF (1999) Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17(4):1155

17.

Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, Foley JP, Riffenburgh RH, Moul JW (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61(3):607–611PubMedCrossRef

18.

Krämer S, Görich J, Gottfried HW, Riska P, Aschoff AJ, Rilinger N, Brambs HJ, Sokiranski R (1997) Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 7 0(838):995–999

19.

Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219(2):432–439PubMed

20.

Parra RO, Wolf RM, Huben RP (1990) The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrences after a radical urological pelvic operation. J Urol 144(3):707–709PubMed

21.

Kapoor DA, Wasserman NF, Zhang G, Reddy PK (1993) Value of transrectal ultrasound in identifying local disease after radical prostatectomy. Urology 41(6):594–597PubMedCrossRef

22.

Scattoni V, Roscigno M, Raber M, Montorsi F, Da Pozzo L, Guazzoni G, Freschi M, Rigatti P (2003) Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 44(4):407–414PubMedCrossRef

23.

Ornstein DK, Colberg JW, Virgo KS, Chan D, Johnson ET, Oh J, Johnson FE (1998) Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 52(6):1047–1054PubMedCrossRef

24.

Bott SR (2004) Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 7(3):211–216PubMedCrossRef

25.

Shekarriz B, Upadhyay J, Wood DP Jr, Hinman J, Raasch J, Cummings GD, Grignon D, Littrup PJ (1999) Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology 54(6):1044–1048PubMedCrossRef

26.

Saleem MD, Sanders H, Abu El Naser M, El-Galley R (1998) Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 51(2):283–286PubMedCrossRef

27.

Zietman AL, Shipley WU, Willett CG (1993) Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. Cancer 71(3):959–969

28.

Connolly JA, Shinohara K, Presti JC Jr, Carroll PR (1996) Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47(2):225–231

29.

Naya Y, Okihara K, Evans RB, Babaian RJ (2005) Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology 66(2):350–355

30.

Scattoni V, Roscigno M, Raber M, Montorsi F, Bertini R, Bua L, Da Pozzo L, Rigatti P (2002) Diagnostic value of ultrasound-guided anastomotic biopsies in patients with high PSA (> or = 0, 4 ng/ml) after radical prostatectomy. Arch Ital Urol Androl 74(3):129–131PubMed

31.

Roscigno M, Cozzarini C, Scattoni V, Bertini R, Da Pozzo L, Pasta A, Montorsi F, Bolognesi A, Fiorino C, Colombo R, Fazio F, Rigatti P (2007) A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy. Radiother Oncol 82(1):30–37PubMedCrossRef

32.

Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231(2):379–385PubMedCrossRef

33.

Silverman JM, Krebs TL (1997) MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 168(2):379–385PubMed

34.

Cosciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, Gualdi GF (2008) Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 190(5):1187–1192CrossRef

35.

Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, Ortega C, Gabriele P, Regge D (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19(3):761–769PubMedCrossRef

36.

Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H, Finn RD, Reddy D, Horowitz SM, Goldsmith SJ, Scher HI (1996) Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 23(6):693–697PubMedCrossRef

37.

Schöder H, Herrmann K, Gönen M, Hricak H, Eberhard S, Scardino P, Scher HI, Larson SM (2005) 2-[18F] fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 1;11(13):4761–4769

38.

Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57(1):108–111PubMedCrossRef

39.

Effert PJ, Bares R, Handt S, Wolff JM, Büll U, Jakse G (1996) Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155(3):994–998PubMedCrossRef

40.

Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36(1):31–35PubMedCrossRef

41.

Haseman MK, Reed NL, Rosenthal SA (1996) Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 21(9):704–713PubMedCrossRef

42.

Sanz G, Robles JE, Giménez M, Arocena J, Sánchez D, Rodriguez-Rubio F, Rosell D, Richter JA, Berián JM (1999) Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 84(9):1028–1031PubMedCrossRef

43.

Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI (2002) Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59(6):913–918PubMedCrossRef

44.

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44(1):32–38 (discussion 38–39)

45.

Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR (2002) Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168(1):273–280PubMedCrossRef

46.

Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, Kibel AS, Andriole GL, Picus J, Welch MJ (2003) 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44(4):549–555PubMed

47.

Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P, Reske SN, Neumaier B (2003) Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42(1):25–30PubMed

48.

Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR (2003) Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30(4):607–611

49.

Reske SN, Blumstein NM, Glatting G (2006) PET and PET/CT in relapsing prostate carcinoma]. Urologe A 45(10):1240, 1242–1244, 1246–1248, 1250

50.

Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN (2002) Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29(10):1380–1384PubMedCrossRef

51.

Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN (2011) The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate Cancer. Eur Urol 59(1):51–60PubMedCrossRef

52.

Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, Soloviev D, Hany TF, Miralbell R (2007) 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99(6):1415–1420 (Epub 2007 Apr 8)

53.

Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, Langsteger W (2006) Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imaging Biol 8(1):43–48PubMedCrossRef

54.

Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100(4):786–793PubMedCrossRef

55.

Crook J, Robertson S, Collin G et al (1993) Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 27:31–37PubMedCrossRef

56.

Yakar D, Hambrock T, Huisman H, Hulsbergen-van de Kaa CA, van Lin E, Vergunst H, Hoeks CM, van Oort IM, Witjes JA, Barentsz JO, Fütterer JJ (2010) Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol 45(3):121–125PubMedCrossRef

57.

Kim CK, Park BK, Park W, Kim SS (2010) Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging 35(2):246–252PubMedCrossRef

58.

Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M 3rd (2004) Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60:1047–1055PubMedCrossRef

59.

Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, Ebora LE, Scardino PT, Koutcher JA, Zakian KL (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy—initial experience. Radiology 236:545–553PubMedCrossRef

60.

Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M (2000) Postradiotherapy prostate biopsies: what do they really mean? results for 498 patients. Int J Radiation Oncol Biol Phys 48(2):355–367

61.

Galosi AB, Lugnani F, Muzzonigro G (2007) Salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. J Endourol 21(1):1–7PubMedCrossRef

62.

Rukstalis DB, Katz A (eds) (2007) Handbook of urologic cryoablation. Infrma UK Ldt, London, pp 31–38

63.

Loch T (2007) Urologic imaging for localized prostate cancer in 2007. World J Urol 25(2):121–129

64.

Larson BT, Collins JM, Huidobro C, Corica A, Vallejo S, Bostwick DG (2003) Gadolinium enhanced MRI in the evaluation of the minimally invasive treatment of the prostate: correlation with histopatologic findings. Urology 62:900–904PubMedCrossRef

65.

Donnely SE, Donnely BJ (2004) Prostater cancer: gadolinium enhanced MR imaging at three weeks compared with needle biopsy at six months after Cryoablation. Radiology 232(3):830–833CrossRef

66.

Shinohara K (2003) Prostate cancer. Cryotherapy. Urol Clin North Am 30:725–736PubMedCrossRef

67.

Chin JL, Touma N, Pautler SE, Guram KS, Bella AJ, Downey DB, Moussa M (2003) Serial histopathology results of salvage cryoablation for prostate cancer after radiation failure. J Urol 170(4 Pt 1):1199–1202

68.

Galosi AB, Muzzonigro G, Polito M Jr, Minardi D, Dellabella M, Lugnani F, Polito M (2000) Role of transrectal ultrasonography in the follow-up of patients treated with prostatic cryosurgery. Arch Ital Urol Androl 72(4):276–281PubMed

69.

Galosi AB, Parri G, Montironi R et al. (2009) Prostate cryoablation as primary treatment of prostate cancer: oncological results with follow-up biopsy. Poster at the 2nd International Workshop Focal Therapy and Imaging in Prostate & Kidney Cancer. Amsterdam, The Nederland June 10–13, 2009

70.

Heidenreich A, Bolla M, Joniau S et al. (2010) Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/prostate%20Cancer%202010%20June%2017th.pdf. Retrieved July 19, 2010

71.

Guideline for the management of clinically localized prostate cancer (2007) update. American Urological Association Web site. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=pc. Retrieved February 10, 2010

72.

Rouviere O, Mege-Lechevallier F, Chapelon JY, Gelet A, Bouvier R, Boutitie F, Lyonnet D (2006) Evaluation of color doppler in guiding prostate biopsy after HIFU ablation. Eur Urol 50:490–497PubMedCrossRef

73.

Rouvière O, Curiel L, Chapelon JY et al (2004) Can color doppler predict the uniformity of HIFU-induced prostate tissue destruction? Prostate 60:289–297PubMedCrossRef

74.

Cirillo S, Petracchini M, D’Urso L, Dellamonica P, Illing R, Regge D, Muto G (2008) Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal highintensity focused ultrasound. BJU Int 102:452–458PubMedCrossRef

75.

Kim CK, Park BK, Lee HM, Kim SS, Kim E (2008) MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 190:1180–1186PubMedCrossRef

76.

Warmuth M, Johansson T, Mad P (2010) Systematic review of the efficacy and safety of High-Intensity Focused Ultrasound for the primary and salvage treatment of prostate cancer. European Urol 58;803–815

Titel: Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU)
verfasst von: Pasquale Martino
Vincenzo Scattoni
Andrea B. Galosi
Paolo Consonni
Carlo Trombetta
Silvano Palazzo
Carmen Maccagnano
Giovanni Liguori
Massimo Valentino
Michele Battaglia
Libero Barozzi
Publikationsdatum: 01.10.2011
Verlag: Springer-Verlag
Erschienen in: World Journal of Urology / Ausgabe 5/2011
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-011-0687-y

Neu im Fachgebiet Urologie

18.04.2024 | Infertilität | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU)

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Urologie

Viele Ärzte haben Probleme mit der Zeugungsfähigkeit

Hochrisiko-Eingriffe für postoperative Übelkeit

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer

The current role of contrast-enhanced ultrasound (CEUS) imaging in the evaluation of renal pathology

Quantitative assessment of urethral vascularity in nulliparous females using high-frequency endovaginal ultrasonography

Computerized transrectal ultrasound of the prostate in a multicenter setup (C-TRUS-MS): detection of cancer after multiple negative systematic random and in primary biopsies

Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study

Collagenase-3 expression by tumor cells and gelatinase B expression by stromal fibroblast-like cells are associated with biochemical recurrence after radical prostatectomy in patients with prostate cancer

Neu im Fachgebiet Urologie

Viele Ärzte haben Probleme mit der Zeugungsfähigkeit

Hochrisiko-Eingriffe für postoperative Übelkeit

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Urologie